Company / R&D Expense
Coya Therapeutics, Inc. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$16.7M
FY2025
5-year range
$4.4M / $16.7M
FY2023-FY2025
Trend
+204.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense changed +204% YoY in FY2025, a notable deviation from the 2-year average annual change of +114%.
Based on SEC 10-K filings.
$17M in FY2025.
Improved from $4M to $17M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d expense increased 204.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.7M | +204.2% |
| FY2024 | $5.5M | +24.7% |
| FY2023 | $4.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026